Arecor Therapeutics PLC Ordinary Shares (AREC)

Industry Biotechnology

This stock can be held in an Investment ISA and an Investment Account

Sell

76.00p

Buy

85.00p

arrow-up0.50p (+0.63%)

Prices updated at 19 Dec 2025, 15:00 GMT

Prices minimum 15 mins delay

Prices in GBX

FTSE All-Share

0.53%

LSE

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Sector

Healthcare

Industry

Biotechnology

Chairman

Dr. Andrew John McGlashan Richards CBE

CEO

Ms. Sarah Jennifer Howell

Most recent earnings

31 Dec 2024

Fiscal year end

31 Dec 2024

Employees

44

Head office

Chesterford Research Park

Saffron Walden

United Kingdom

CB10 1XL

+44 1223426060

info@arecor.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Dr. Andrew John McGlashan Richards CBE Non-Executive Director, Chairman	-
Mr. Mohammad Sohail Fazeli Non-Executive Director	-
Mr. Jeremy Lewis Morgan Non-Executive Director	-
Mr. David Ellam Executive Director, Chief Financial Officer and Company Secretary	-
Ms. Sarah Jennifer Howell Executive Director, Chief Executive Officer	-

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
Unicorn Asset Management Ltd	1,198,828
Unicorn AIM VCT Series 3 ORD	1,198,828
Hargreave Hale Limited	517,518
Hargreave Hale AIM VCT	517,518
Calculus Capital Limited	415,152

Director dealings

Date chevron-l-regular chevron-r-regular	Action
19 May 2025	Purchase
19 May 2025	Purchase
13 May 2025	Purchase

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.